E-LIB Suche - Ergebnisse für: Schädlich, Peter K.

1

Annual cost of hospitalization, inpatient rehabilitation, a..:

Schädlich, Peter K. ; Klussmann ; Chen.
ClinicoEconomics and Outcomes Research. , 2013

Link: https://doi.org/10.2147/..

2

Association Between Gout and All-Cause as well as Cardiovas..:

Lottmann, Kathrin ; Chen, Xiaoyu ; Schädlich, Peter K.
Current Rheumatology Reports. 14 (2012) 2 - p. 195-203 , 2012

Link: https://doi.org/10.1007/..

3

Health economic evaluations comparing insulin glargine with..:

Hagenmeyer, Ernst-Günther ; Koltermann, Katharina C ; Dippel, Franz-Werner.
Cost Effectiveness and Resource Allocation. 9 (2011) 1 - p. 15 , 2011

Link: https://doi.org/10.1186/..

4

Cost Effectiveness of Enoxaparin as Prophylaxis against Ven..:

Schädlich, Peter K. ; Kentsch, Michael ; Weber, Manfred...
PharmacoEconomics. 24 (2006) 6 - p. 571-591 , 2006

Link: https://doi.org/10.2165/..

5

Modelling cost effectiveness and cost utility of sequential..:

Schädlich, Peter K. ; Zeidler, Henning ; Zink, Angela...
PharmacoEconomics. 23 (2005) 4 - p. 395-420 , 2005

Link: https://doi.org/10.2165/..

6

Modelling cost effectiveness and cost utility of sequential..:

Schädlich, Peter K. ; Zeidler, Henning ; Zink, Angela...
PharmacoEconomics. 23 (2005) 4 - p. 377-393 , 2005

Link: https://doi.org/10.2165/..

7

Cost Effectiveness of Ramipril in Patients at High Risk for..:

Schädlich, Peter K. ; Brecht, Josef Georg ; Rangoonwala, Badrudin.
PharmacoEconomics. 22 (2004) 15 - p. 955-973 , 2004

Link: https://doi.org/10.2165/..

8

Cost Effectiveness of Ramipril in Patients with Non-Diabeti..:

Schädlich, Peter K. ; Brecht, Josef Georg ; Brunetti, Massimo...
PharmacoEconomics. 19 (2001) 5 - p. 497-512 , 2001

Link: https://doi.org/10.2165/..

9

Economic Evaluation of Specific Immunotherapy Versus Sympto..:

Schädlich, Peter K. ; Brecht, Josef G.
PharmacoEconomics. 17 (2000) 1 - p. 37-52 , 2000

Link: https://doi.org/10.2165/..

10

The Cost Effectiveness of Acamprosate in the Treatment of A..:

Schädlich, Peter K. ; Brecht, Josef Georg
PharmacoEconomics. 13 (1998) 6 - p. 719-730 , 1998

Link: https://doi.org/10.2165/..

11

Cost-Effectiveness Analysis of Ramipril in Heart Failure af..:

Schädlich, Peter K. ; Huppertz, Eduard ; Brecht, Josef Georg
PharmacoEconomics. 14 (1998) 6 - p. 653-669 , 1998

Link: https://doi.org/10.2165/..

12

Economic Evaluation of the Cardiac Insufficiency Bisoprolol..:

Schädlich, Peter K. ; Paschen, Britta ; Brecht, Josef Georg
PharmacoEconomics. 13 (1998) 1 - p. 147-155 , 1998

Link: https://doi.org/10.2165/..

13

Wirtschaftlichkeit von Bisoprolol bei Herzinsuffizienz: Öko..:

Schädlich, Peter K. ; Paschen, Britta ; Brecht, Josef Georg
Medizinische Klinik - Intensivmedizin und Notfallmedizin. 92 (1997) 8 - p. 499-504 , 1997

Link: https://doi.org/10.1007/..

14

Asthma und Antiasthmatika ‐ Das neue Therapiekonzept, Wirks..:

Schädlich, Peter K.
Pharmazie in unserer Zeit. 25 (1996) 3 - p. 163-163 , 1996

Link: https://doi.org/10.1002/..

15

Annual cost of hospitalization, inpatient rehabilitation, a..:

Klussmann, Jens P ; Schädlich, Peter K ; Chen, Xiaoyu.
info:eu-repo/semantics/altIdentifier/doi/10.2147/CEOR.S43393. , 2013

Link: https://www.dovepress.co..